PROTAC Technology: Programmable Protein Degradation

What Is PROTAC Technology?

PROTAC (PROteolysis TArgeting Chimera) technology is a therapeutic modality that uses bifunctional small molecules to recruit the cell's own ubiquitin-proteasome system (UPS) to degrade disease-causing proteins. A PROTAC consists of three parts: a target-binding warhead, an E3 ubiquitin ligase ligand, and a linker connecting them. When the PROTAC brings the target protein and E3 ligase into proximity, the E3 ligase ubiquitinates the target, marking it for degradation by the 26S proteasome.

This approach is revolutionary because it expands the druggable proteome—approximately 85% of proteins lack suitable binding pockets for traditional inhibitors. PROTACs can target transcription factors, scaffolding proteins, and other "undruggable" targets. Additionally, PROTACs are catalytic: a single molecule can facilitate the degradation of multiple target protein copies, enabling lower effective doses.

Data: PROTAC Clinical Landscape

Source: Arvinas corporate data, ClinicalTrials.gov, and industry analysis.

How: PROTAC Design and Development

Step 1: Target Protein Selection

1. Identify disease-causing protein requiring degradation
2. Confirm protein is druggable by PROTAC approach:
   • Surface-exposed lysines for ubiquitination
   • Known binders or covalent warheads for target recruitment
3. Validate that degradation (not just inhibition) provides therapeutic benefit
4. Consider target abundance and turnover rate

Step 2: Warhead Selection

1. Use known inhibitors as target-binding warheads:
   • Small molecule inhibitors (kinase inhibitors, receptor antagonists)
   • Covalent binders for targets lacking high-affinity ligands
2. Optimize warhead affinity (Kd < 100 nM preferred)
3. Identify attachment points for linker that don't disrupt binding

Step 3: E3 Ligase Selection

1. CRBN (cereblon): Most common, orally bioavailable ligands (thalidomide analogs)
2. VHL: Second most common, different substrate scope
3. IAP (inhibitor of apoptosis): Alternative for CRBN/VHL-resistant targets
4. Novel E3 ligases: DCAF15, MDM2, RNF114 (expanding the repertoire)
5. Consider tissue expression of E3 ligase (e.g., CRBN highly expressed in hematological tissues)

Step 4: Linker Optimization

1. Screen linker lengths (typically 8-20 atoms)
2. Vary linker composition (PEG, alkyl, rigid linkers)
3. Optimize for:
   • Ternary complex formation (target-PROTAC-E3 cooperativity)
   • Cellular permeability
   • Metabolic stability
   • Hook effect minimization
4. Use structure-based design if target-E3 complex structure is available

Step 5: Preclinical Validation

1. Confirm target degradation (Western blot, proteomics)
2. Measure DC50 (concentration for 50% degradation) and Dmax (max % degradation)
3. Assess downstream functional effects (proliferation, apoptosis)
4. Evaluate selectivity (quantitative proteomics for off-target degradation)
5. Pharmacokinetic/pharmacodynamic (PK/PD) modeling

Comparison: PROTACs vs. Traditional Inhibitors

Summary: Key Takeaways

1. PROTACs catalytically degrade target proteins, enabling treatment of "undruggable" targets.
2. Two PROTACs (ARV-110, ARV-471) are in Phase III, with first approvals expected by 2025-2026.
3. Linker optimization is critical for ternary complex formation and cellular activity.
4. CRBN and VHL are the primary E3 ligases, but expanding the repertoire is essential for broader target coverage.
5. The total protein degradation market is projected to reach $15 billion by 2030.

References

1. Bekes, M. et al. "PROTAC targeted protein degraders: the past is prologue." Nature Reviews Drug Discovery 21, 181-200 (2022).
2. Burslem, G.M. & Crews, C.M. "Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery." Cell 181, 102-114 (2020).
3. Arvinas. "ARV-471 Phase 3 VERITAC-2 Trial Initiated." Press release (2023).
4. Bond, M.J. & Crews, C.M. "Proteolysis Targeting Chimeras (PROTACs): Past, Present, and Future." Annual Review of Pharmacology (2024).
5. FDA. "Targeted Protein Degradation: Considerations for Drug Development." FDA Workshop (2023).